Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.
|Articles|July 12, 2013
Supplements and Featured Publications
- The Clinical, Social, and Economic Implications of Neurogenic Bladder in Managed Care: Optimizing Pa
- Volume 19
- Issue 10 Suppl
Post Test: The Clinical, Social, and Economic Implications of Neurogenic Bladder in Managed Care: Optimizing Patient Management and Outcomes
Advertisement
Instructions
After reading “The Clinical, Social, and Economic Implications of Neurogenic Bladder in Managed Care: Optimizing Patient Management and Outcomes,” complete the program evaluation and select the single best answer to each of the posttest questions.
A statement of continuing education credit will be provided to those physicians and pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher on the posttest.
Articles in this issue
about 13 years ago
Optimizing Therapy and Management of Neurogenic Bladderabout 13 years ago
The Epidemiology and Pathophysiology of Neurogenic BladderAdvertisement
Related to this article
Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.
Outpatient dialysis for unfunded patients with ESKD cut ED reliance and costs, while church-based CKD screening improved blood pressure.
Asian expert consensus updates mantle cell lymphoma treatment guidelines, highlighting uneven BTK inhibitor, ibrutinib and CAR T-cell access across Asia.
At ASN Kidney Week 2026, nephrologists said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
Insulin icodec-abae becomes the first once-weekly basal insulin cleared for children 10 years and older with type 2 diabetes.
At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
3
How ID, HIV Clinicians Can Influence Policy in an Election Year
4
It’s the Best of Times and Worst of Times for Cancer Care in Tampa
5